Supporting Information for

Imine Hydrogenation by Alkylaluminum Catalysts

Jillian A. Hatnean^a, Jordan W. Thomson^b, Preston A. Chase^b and Douglas W Stephan^a*

S1. Synthesis and Isolation of Compounds

General considerations

All synthetic manipulations were carried out under an atmosphere of dry, O₂-free N₂ employing an MBraun glove box and a Schlenk vacuum-line. Toluene was purified with a Grubbs-type column system manufactured by Innovative Technology and dispensed into thick-walled glass Schlenk bombs equipped with Young-type Teflon valve stopcocks. Chloroform-d and bromobenzene- d_5 were each dried over CaH₂, vacuum-transferred into a Young bomb, and stored over 4 Å molecular sieves. Toluene- d_8 and benzene- d_6 were dried over Na/benzophenone, vacuum-transferred into a Young bomb, and stored over 4 Å molecular sieves. All solvents were thoroughly degassed after purification (three freeze-pump-thaw cycles). NMR spectra were recorded at 25 °C on a Bruker Avance 400 MHz spectrometer. Chemical shifts are given relative to SiMe₄ and referenced to the residual solvent signal (${}^{1}H$, ${}^{13}C$) or relative to an external standard (²⁷Al: Al(NO₃)₃). Chemical shifts are reported in ppm and coupling constants as scalar values in Hz. Elemental analyses were performed in house by ANALEST on a 2400 Series II CHNS Analyzer. Diisobutylaluminum hydride (DIBAL, 1) and commercially available substrates MeN=CHPh, (Me₃Si)N=CHPh, PhN=CHPh, (Ph₂CH)N=CHPh, tBuN=CHPh, (PhO₂S)N=CHPh, and 1,3,3-trimethyl-2-methyleneindoline were obtained from Sigma-Aldrich. Commercially available 1-cyclohexen-1-ylpiperidine was obtained from Alfa Aesar. Commercially available BnN=CHPh was obtained from Acros Organics. Triisobutylaluminum (TIBAL, 2) was purchased from Strem. Liquid substrates were stored over 4 Å molecular sieves or distilled from TIBAL and stored in an inert atmosphere glovebox. Solid substrates were dried in vacuo and stored in an inert atmosphere glovebox. Hydrogen gas (Grade 5.0) was obtained from Linde and purified through a Matheson Model 450B or Matheson Nanochem WeldAssureTM gas purifier. The compound iBu_2AlD^1 and substrates PhN=CH(p-BrC₆H₄),² $tBuN=CH(p-tBuC_6H_4)$,³ (2,6-Me₂Ph)N=C(Me)Ph,⁴ $tBuN=CH(p-NMe_2C_6H_4)$,⁵ $tBuN=CH(m-tBuC_6H_4)$,⁶ $tBuN=CH(m-tBuC_6H_4)$,⁵ $tBuN=CH(m-tBuC_6H_4)$,⁵ $tBuN=CH(m-tBuC_6H_4)$,⁵ $tBuN=CH(m-tBuC_6H_4)$,⁶ $tBuN=CH(m-tBuN=CH(m-tBuC_6H_4)$,⁶ $tBuN=CH(m-tBuN=CH(m-tBuN=CH_6H_4)$,⁶ BrC_6H_4),⁶ $tBuN=CH(p-BrC_6H_4)$,⁷ $(p-ClC_6H_4)N=CHPh^8$ and $tBuN=CH(m-OMeC_6H_4)^6$ were prepared via literature methods. A series of hydrogenation experiments were performed either in a Parr Pressure reactor or a J. Young tube. Details are provided below.

General procedure for elevated pressure reductions: In a N₂ filled glove box, substrate (Entries 1, 5–8, 10–14: 0.7 mmol; Entries 2–4, 9 and 15: 0.5 mmol) was weighed in a 2 dram vial and dissolved in toluene (0.3 ml). To this was added catalyst (5 mol% of 1 (DIBAL) or 10 mol% of 2 (TIBAL)) and the imine/catalyst solution was thoroughly mixed. Seven vials were then transferred to a Parr pressure reactor. The reactor was sealed, removed from the glovebox and attached to a thoroughly purged hydrogen gas line. The reactor was purged five times at 50 atm hydrogen and five times at 92 atm H₂. The reactor was sealed under 92 atm H₂, and placed on a stir plate heated to 100 °C (final pressure 102 atm H₂) for 24 h. The reactor was cooled, slowly vented and an NMR sample was taken in CDCl₃. Conversion of unsaturated substrate to amine product was determined by ¹H NMR spectroscopy.


General procedure for amine isolation: The solvent was removed *in vacuo*, and the resulting oil/solid dissolved in EtOAc. To this, 2 mL of water was added, and the organic layer decanted. The aqueous layer was extracted 2 x 5 mL of EtOAc. The combined organic fractions were treated with MgSO₄, filtered through a plug of Celite, and dried *in vacuo*. Analysis by ¹H NMR spectroscopy revealed that compound *N*-benzyl(trimethylsilyl)amine decomposed upon aqueous workup. Compound *N*-benzylaniline required additional column chromatography for purification.


Product characterization data:

Products (isolated and crude) were characterized by ${}^{1}H$ and ${}^{13}C{}^{1}H$ NMR spectroscopy and compared to literature values where applicable.

NH NH NH NH NH NMR (400 MHz, CDCl₃): δ 7.35-7.31 (m, 5H, C₆H₅); 3.75 (s, 2H, CH₂); 2.46 (s, 3H, CH₃). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 139.2, 128.5, 128.4 and 128.3 Ph (Ph-C); 56.3 (CH₂); 36.2 (CH₃).

C); 48.3 (*C*H₂).






N-(4-bromobenzyl)aniline (entry 4): ref¹² ¹H NMR (400 MHz, CDCl₃): δ 7.45 (d, 2H, C₆H₅, ³J_{HH} = 8 Hz) 7.25-7.18 (m, 3H, C₆H₅); 6.72 and 6.62 (d, 4H, *p*-BrC₆H₄, ³J_{HH} = 8.7 Hz); 4.29 (d, 2H, CH₂, ³J_{HH} = 6.9 Hz); 4.03 (br m, 1H, NH). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 147.0, 138.1, 129.9, 129.2, 129.1, 118.2 and 113.4 (Ph–C); 47.9 (CH₂).

N-(4-*tert*-butylbenzyl)-*tert*-butylamine (entry 5): (white solid, 149 mg, 97 % isolated yield) ¹H NMR (400 MHz, CDCl₃): δ 7.47 and 7.36 (d, 4H, *p*-*t*BuC₆*H*₄, ³*J*_{HH} = 7 Hz); 3.65 (d, 2H, C*H*₂, ³*J*_{HH} = 7.7 Hz); 1.34 (s, 9H, *p*-*t*Bu-C*H*₃); 1.17 (s, 9H, *t*Bu-C*H*₃); 0.81 (br t, 1H, N*H*). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 144.1, 139.2, 132.9 and 126.8 (Ph-C); 57.5 and 50.6 (*t*Bu-C); 46.6 (CH₂); 29.6 and 29.1

 $(tBu-CH_3).$



NH H₃C Ph H

NΗ

tBu 、

97 % isolated yield) ¹H NMR (400 MHz, CDCl₃): δ 7.32-7.10 (m, 15H, C₆H₅); 4.88 (d, 1H, CH, ³J_{HH} = 3.8 Hz); 3.76 (d, 1H, CH₂, ³J_{HH} = 7.6 Hz); 1.85 (m, 1H, NH). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 144.1, 140.6, 128.4, 128.3, 128.2, 127.4, 127.1 and 127.0 (Ph–C); 66.5 (CH); 51.9 (CH₂).


N-benzyl-diphenylmethylamine (entry 6): ref¹³ (pale yellow solid, 186 mg,

rac-2,6-dimethyl-*N*-(1-phenylethyl)aniline (entry 7): (pale yellow solid, 151 mg, 94 % isolated yield) ¹H NMR (400 MHz, CDCl₃): δ 7.29 and 7.20 (m, 5H, C₆H₅); 7.02 (d, 2H, *m*-(2,6-Me₂)C₆H₃, ³J_{HH} = 8 Hz); 6.88 (t, 1H, *p*-(2,6-Me₂)C₆H₃, ³J_{HH} = 8 Hz); 4.35 (dq, 1H, CH, ³J_{HH} = 10.3, 6.8 Hz); 3.20 (d, 1H, NH, ³J_{HH} = 10.3 Hz); 2.20 (s, 6H, (2,6-CH₃)₂Ph); 1.52 (s, 3H, CH₃, ³J_{HH} = 6.8 Hz). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 145.3, 145.0, 129.1, 128.4, 128.2, 127.0, 126.1 and 121.7 (Ph–C); 56.8 (CH); 22.6 (CH₃); 18.9 (2,6–CH₃).


N-benzyl-*tert*-butylamine (entry 8): ref¹⁴ ¹H NMR (CDCl₃, 400 MHz): δ 7.25 and 7.23 (m, 4H, *o* and *m*-Ph-*H*); 7.15 (tt, 1H, *p*-Ph-*H*, ³*J*_{HH} = 6.9 Hz, ⁴*J*_{HH} = 1.6 Hz); 3.65 (s, 2H, C*H*₂); 1.11 (s, 9H, *t*Bu-C*H*₃). ¹³C{¹H} NMR (CDCl₃, 101 Ph MHz): δ 141.4, 128.2, 128.1 and 126.6 (Ph-*C*); 50.5 (*t*Bu-*C*); 47.1 (*C*H₂); 29.0 (*t*Bu-CH₃).



Dibenzylamine (entry 9): ¹**H NMR (400 MHz, CDCl₃):** δ 7.39-7.33 (m, 10H, C₆*H*₅); 3.79 (d, 2H, C*H*₂, ³*J*_{HH} = 6.5 Hz); 1.51 (br t, 1H, N*H*). ¹³C{¹H} **NMR (101 MHz, CDCl₃):** δ 140.4, 129.1, 128.4 and 127.0 (Ph–C); 53.2 (CH₂).



N-(4-dimethylaminobenzyl)-*tert*-butylamine (entry 10): ¹H NMR (400 MHz, CDCl₃): δ 7.51 and 7.45 (d, 4H, *p*-NMe₂C₆H₄, ³J_{HH} = 9.1 Hz); 3.65 (d, 2H, CH₂, ³J_{HH} = 7.7 Hz); 2.38 (s, 6H, N(CH₃)₂); 1.20 (s, 9H, *t*Bu–CH₃). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 136.2, 131.5, 130.0 and 120.5 (Ph–C); 50.8 (*t*Bu–C); 46.7 (CH₂); 29.7 (NCH₃); 29.2 (*t*Bu–CH₃).



N-(3-bromobenzyl)-*tert*-butylamine (entry 11): ¹H NMR (400 MHz, CDCl₃): δ 7.41–7.30, 7.23 and 7.18 (m, 4H, C₆H₅); 3.73 (br s, 2H, CH-2); 1.21 (s, 9H, *t*Bu–CH₃). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 138.5, 133.7, 128.4, 128.1, 127.9 and 125.4 (Ph–C); 50.4 (*t*Bu–C); 46.8 (CH₂); 29.1 (*t*Bu–CH₃).


*t*Bu NH

Br

N-(4-bromobenzyl)-*tert*-butylamine (entry 12): ¹H NMR (400 MHz, CDCl₃): δ 7.43 and 7.21 (d, 4H, *p*-BrC₆*H*₄, ³*J*_{HH} = 8.3 Hz); 3.65 (d, 2H, C*H*₂, ³*J*_{HH} = 7.8 Hz); 1.18 (s, 9H, *t*Bu–C*H*₃); 0.89 (br t, 1H, N*H*). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 140.7, 131.4, 130.0 and 120.4 (Ph–C); 50.7 (*t*Bu–C); 46.6 (CH₂); 29.2 (*t*Bu–CH₃).

Ph S NH

N-benzylbenzenesulfonamide (entry 13): ref¹⁵ ¹H NMR (400 MHz, CDCl₃): δ 8.05 (d, 2H, SO₂C₆H₅, ³J_{HH} = 8 Hz); 7.89 (m, 3H, SO₂C₆H₅); 7.57-7.48 (m, 5H, C₆H₅); 5.33 (t, 1H, NH, ³J_{HH} = 6 Hz); 4.13 (d, 2H, CH₂, ³J_{HH} = 6 Hz). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 140.3, 136.5, 129.3, 128.7, 127.9 and 127.3 (Ph–C); 47.5 (CH₂).




N-benzyl-4-chloroaniline (entry 14): ref¹² ¹H NMR (400 MHz, CDCl₃): δ 7.33-7.26 (m, 5H, C₆H₅); 7.10 and 6.43 (d, 4H, *p*-ClC₆H₄, ³J_{HH} = 8.3 Hz); 4.15 (d, 2H, CH₂, ³J_{HH} = 7.7 Hz); 3.95 (br, 1H, NH). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 146.6, 138.8, 129.2, 128.8, 127.5, 122.1 and 113.9 (Ph–C); 48.2 (CH₂).

*t*Bu NH OMe

N-(3-methoxybenzyl)-*tert*-butylamine (entry 15): ref¹⁶ ¹H NMR (CDCl₃, 400 MHz): δ 7.22 (dd, 1H, 5–Ph–*H*, ³*J*_{HH} = 8.0 Hz, ³*J*_{HH} = 8.0 Hz); 6.93 (s, 1H, 2–Ph–*H*); 6.93 (m, 1H, 4–Ph–*H*); 6.78 (dd, 1H, 6–Ph–*H*, ³*J*_{HH} = 8.3 Hz, ³*J*_{HH} = 2.2 Hz); 3.80 (s, 1H, OC*H*₃); 3.71 (s, 2H, C*H*₂); 1.17 (s, 9H, *t*Bu–C*H*₃). ¹³C{¹H} NMR (CDCl₃, 101


MHz): δ 158.7, 141.8, 128.4, 119.6, 121.8, and 111.4 (Ph–*C*); 54.1 (O*C*H₃); 49.9 (*t*Bu–*C*); 46.2 (*C*H₂); 28.0 (*t*Bu–*C*H₃).



Synthesis of $[iBu_2AIN(Ph)(p-BrBn)]_2$ (3). A 1.0 M solution of DIBAL in toluene (0.35 mL, 0.35 mmol) was added to the imine PhN=CH(p-BrC₆H₄) (91 mg, 0.35 mmol) in a vial. The red solution was left on the shelf at room temperature overnight, whereupon colourless X-ray quality crystals precipitated from the solution. The supernatant was decanted, the crystals washed with a small amount of cold pentane, then dried *in vacuo* yielding a white solid (131 mg, 92% yield).

¹H NMR (400 MHz, C₆D₅Br): δ 7.11 (d, 4H, *m*-C₆H₄Br, ³J_{HH} = 8.8 Hz); 7.04 (m, 8H, *o/m*-C₆H₅); 6.83 (t, 2H, *p*-C₆H₅, ³J_{HH} = 6.8 Hz); 6.72 (d, 4H, *o*-C₆H₄Br, ³J_{HH} = 8.8 Hz); 4.47 (s, 4H,

Bn-C*H*₂); 2.01 and 1.84 (m, 4H, *i*Bu-C*H*); 1.09, 1.06, 0.99 and 0.95 (d, 24H, *i*Bu-C*H*₃, ${}^{3}J_{\text{HH}} = 6.6$ Hz); 0.40, 0.38, 0.24 and 0.23 (d, 8H, *i*Bu-C*H*₂, ${}^{3}J_{\text{HH}} = 7.6$, 7.3, 7 Hz). ${}^{13}\text{C}\{{}^{1}\text{H}\}$ NMR (101 MHz, C₆D₅Br): δ 145.8, 139.6, 130.9, 129.2, 128.6, 128.2, 123.9 and 123.6 (Ar-C); 53.3 (CH₂); 27.9, 27.6, 27.5 and 27.4 (*i*Bu-CH₃); 25.9 and 25.6 (*i*Bu-CH₂); 21.4 and 21.0 (*i*Bu-CH). ${}^{27}\text{AI}$ NMR (104 MHz, C₆D₅Br): δ 67.6 (br s, $W_{1/2} = 4076$ Hz). Anal. Calcd. for C₄₂H₅₈Al₂Br₂N₂: C 62.69%, H 7.26%, N 3.48%. Found C 62.31%, H 6.99%, N 3.51%.



Synthesis of $[iBu_2Al(N(tBu)Bn)]_2$, (4). A 1.0 M solution of DIBAL in toluene (0.35 mL, 0.35 mmol) was added to the imine tBuN=CH(Ph) (57 mg, 0.35 mmol) in a vial. The colourless solution was allowed to react for 1 h and the solvent removed *in vacuo* yielding a colourless oil. (101 mg, 95% yield).

¹Bn ¹Bu ¹H NMR (400 MHz, tol- d_8): δ 7.12 (d, 4H, o-C₆ H_4 Br, ³ J_{HH} = 8.4 Hz); 7.02 and 6.95 (m, 6H, m/p-C₆ H_5); 4.19 (s, 4H, Bn-C H_2); 2.07 (m, 4H, *i*Bu-CH); 1.11 and 1.10 (d, 24H, *i*Bu-C H_3 , ³ J_{HH} = 6.6 Hz); 0.53 (m, 8H, *i*Bu-C H_2). ¹³C{¹H} NMR (101 MHz, tol- d_8): δ 141.0, 128.5, 128.2 and 127.4 (Ar-C); 58.2 (CH₂); 53.2 (*t*Bu-C); 31.6 (*t*Bu-CH₃); 28.5 and 28.2 (*i*Bu-CH₃); 28.2 and 28.1 (*i*Bu-CH₂); 26.9 (*i*Bu-CH). ²⁷Al NMR (104 MHz, tol- d_8): δ 74.2 (br s, $W_{1/2}$ = 3388 Hz).

S2. Mechanism

Activation of dihydrogen by 3. In an inert atmosphere glovebox, $[iBu_2AlN(Ph)(p-BrBn)]_2$ (0.35 mmol) was dissolved in C₆D₅Br and placed in a J. Young NMR tube. The tube was sealed and subjected to three freeze-pump-thaw cycles. The tube was then frozen, evacuated and backfilled with 4 atm H₂ gas. The tube was thawed and heated to 100 °C. Analysis of the crude reaction mixture after 10 h by ¹H NMR spectroscopy revealed the presence of unreacted 3 and free amine PhNHCH₂(*p*-BrC₆H₄). The reaction was allowed to continue overnight at 100 °C. The solvent was removed *in vacuo* and the residue redissolved in CDCl₃. The ¹H NMR spectra below depict the change in CH₂ chemical shift over time:




Figure S2 – ¹H NMR spectra (400 MHz) showing the change in CH₂ chemical shift over time for the reaction of $[iBu_2AIN(Ph)(p-BrBn)]_2$ (**3**) with H₂ at 100 °C in C₆D₅Br overnight.

Activation of D_2 by 3. The activation of D_2 was carried out in an analogous manner to that reported above for the activation of H₂; however, deuterium gas was used in place of hydrogen gas, and C₆H₅Br was used in place of C₆D₅Br. Analysis of the crude reaction mixture by ¹H NMR spectroscopy showed a broad singlet for the CH₂ protons at δ 4.11, but no distinguishable resonance at δ 3.95 associated with NH of the corresponding amine. The ²H NMR spectrum displayed a weak, broad peak at δ 4 with no resolved coupling. These data support the formation of PhNDCH₂(*p*-BrBn).

The reaction was allowed to proceed for 1 week at 100 °C. Analysis of the crude reaction mixture by ¹H NMR spectroscopy showed a broad multiplet for the CH₂ protons at δ 4.11 accompanied with a decreased intensity, and a new broad, unresolved multiplet at δ 3.9 associated with NH of the corresponding amine. The ²H NMR spectrum displayed two weak, broad peaks at δ 4.1 and 4.0 with no resolved coupling These data support a reversible mechanism enabling deuterium scrambling resulting in a mixture of products: PhN(H/D)CH₂(*p*-BrBn), PhN(H/D)CHD(*p*-BrBn) and PhNDCD₂(*p*-BrBn).

Stoichiometric reaction of iBu_2AID , (2,6-Me₂Ph)N=C(Me)Ph and H₂. In a N₂ filled glove box, (2,6-Me₂Ph)N=C(Me)Ph (63 mg, 0.3 mmol) was weighed in a 2 dram vial dissolved in toluene (0.3 ml). To this was added iBu_2AID (40 mg, 0.3 mmol) and the solution was thoroughly

mixed. Initial analysis by ²H NMR spectroscopy revealed a weak multiplet with 5 lines at δ 4.6 with a ³*J*_{DH} value of 2.6 Hz (Figure S3) indicative of CD coupling to CH₃ (partial 1:3:6:7:6:3:1 septet). The corresponding 1:1:1 triplet in the ¹H NMR could not be located as it coincides with the resonance associated with diethyl ether (*vide infra*).

The vial was then transferred to a Parr pressure reactor. The reactor was sealed, removed from the glovebox and attached to a thoroughly purged hydrogen gas line. The reactor was purged five times at 50 atm hydrogen and five times at 92 atm H₂. The reactor was sealed under 92 atm H₂, and placed on a stir plate heated to 100 °C (final pressure 102 atm H₂) for 2 h. The reactor was cooled, slowly vented and an NMR sample was taken. Conversion of unsaturated substrate to amine product was determined by ¹H NMR spectroscopy to be quantitative. The ¹H NMR spectrum displayed a broad 1:1:1 triplet at δ 3.2 for the NH proton coupled to CD with a ³*J*_{HD} value of 1.6 Hz. This fails to integrate properly with the CH₃ resonance, presumably due to H/D scrambling. A broad resonance can be located in the baseline at δ 4.6 due to CH. The ²D NMR spectrum revealed a weak, broad resonance at δ 4.6 for CD.




Figure S3 – ²H NMR spectrum (61.4 MHz) showing 5 lines of a 1:3:6:7:6:3:1 septet (${}^{3}J_{DH} \sim 2.6$ Hz) for the stoichiometric reaction of *i*Bu₂AlD and (2,6-Me₂Ph)N=C(Me)Ph in toluene before H₂ addition.

Stoichiometric reaction of *i*Bu₂AlD, *t*BuN=CHPh and H₂. This reaction was carried out in an analogous manner to that reported above for (2,6-Me₂Ph)N=C(Me)Ph; however *t*BuN=CHPh (45 mg, 0.3 mmol) was used as the substrate. The ¹H NMR spectrum displayed a broad singlet at δ 3.6 for the CH₂ protons. The ²D NMR spectrum was silent.

Note: The above reactions with iBu_2AID took place in the presence of diethyl ether that could not be removed following its synthesis, even after repetitive distillations. This displays catalyst tolerance toward ether functionalities.

S3. References

(1) Eisch, J. J.; Rhee, S.-G. J. Am. Chem. Soc. 1974, 96, 7276.

(2) Iovel, I.; Golomba, L.; Fleisher, M.; Popelis, J.; Grinberga, S.; Lukevics, E. Chem. Heterocycl. Compd. (N. Y., NY, U. S.) **2004**, 40, 701.

- (3) Nanni, D.; Pareschi, P.; Walton, J. C. J. Chem. Soc., Perkin Trans. 2 2002, 1098.
- (4) Dash, C.; Shaikh, M. M.; Butcher, R. J.; Ghosh, P. Inorg. Chem. 2010, 49, 4972.

(5) Boyd, D. R.; Coulter, P. B.; Sharma, N. D.; Jennings, W. B.; Wilson, V. E. *Tetrahedron Lett.* **1985**, *26*, 1673.

- (6) Guimond, N.; Fagnou, K. J. Am. Chem. Soc. 2009, 131, 12050.
- (7) Markowicz, T.; Skolimowski, J.; Skowronski, R. Pol. J. Chem. 1981, 55, 2505.
- (8) Gupta, N.; Naaz, R.; Nigam, G. D. Int. J. Pharma Bio Sci. 2010, 1, 224.
- (9) Adima, A.; Bied, C.; Moreau, J. J. E.; Man, M. W. C. *Eur. J. Org. Chem.* 2004, 2582.

(10) Barany, M. J.; Hammer, R. P.; Merrifield, R. B.; Barany, G. J. Am. Chem. Soc. **2005**, *127*, 508.

(11) Bagal, D. B.; Watile, R. A.; Khedkar, M. V.; Dhake, K. P.; Bhanage, B. M. Catal. Sci. Technol. 2012, 2, 354.

(12) Sreedhar, B.; Reddy, P. S.; Devi, D. K. J. Org. Chem. 2009, 74, 8806.

(13) Likhar, P. R.; Arundhathi, R.; Kantam, M. L.; Prathima, P. S. *Eur. J. Org. Chem.* **2009**, 5383.

(14) Froyen, P.; Juvvik, P. Tetrahedron Lett. 1995, 36, 9555.

(15) Shi, F.; Tse, M. K.; Zhou, S.; Pohl, M.-M.; Radnik, J.; Huebner, S.; Jaehnisch, K.; Brueckner, A.; Beller, M. J. Am. Chem. Soc. **2009**, 131, 1775.

(16) Farrell, J. M.; Hatnean, J. A.; Stephan, D. W. J. Am. Chem. Soc. 2012, 134, 15728.